Optimized anti-tuberculosis duration for drug-susceptible pulmonary tuberculosis-diabetes mellitus comorbidities: study protocol for a multicenter randomized controlled trial

被引：0
|
作者：
Peize Zhang [1 ]
Huaifang Shi [2 ]
Yongping Xie [3 ]
Jiemei Liang [3 ]
Qiumeng Hu [4 ]
Liang Fu [1 ]
Yuxiang Wang [5 ]
Jie Tan [1 ]
Senlin Zhan [1 ]
Hongjuan Qin [1 ]
Guanghui Xu [1 ]
Guofang Deng [1 ]
机构：
[1] Third People’s Hospital of Shenzhen,Department of Pulmonary Medicine and Tuberculosis
[2] Shenzhen Clinical Research Center for Tuberculosis,School of Public Health
[3] Shenzhen University Medical School,undefined
[4] Shenzhen University,undefined
[5] Jiangmen Institute of Tuberculosis Prevention and Control,undefined
[6] Shenzhen University Medical School,undefined
[7] Shenzhen University,undefined
来源：
BMC Pulmonary Medicine | / 24卷 / 1期
关键词：
Drug-susceptible pulmonary tuberculosis (PTB); Type 2 diabetes(DM); Treatment duration; Unfavorable outcome; Treatment success;
D O I：
10.1186/s12890-024-03271-8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 47 条
  • [1] Role of Diabetes Mellitus on Treatment Effects in Drug-susceptible Initial Pulmonary Tuberculosis Patients in China
    Ma Yan
    Huang Mai Ling
    Li Tao
    Du Jian
    Shu Wei
    Xie Shi Heng
    Wang Hong Hong
    Zhu Guo Feng
    Tan Shou Yong
    Fu Yan Yong
    Ma Li Ping
    Zhang Lian Ying
    Liu Fei Ying
    Hu Dai Yu
    Zhang Yan Ling
    Li Xiang Qun
    Liu Yu Hong
    Li Liang
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2017, 30 (09) : 671 - 675
  • [2] Role of Diabetes Mellitus on Treatment Effects in Drug-susceptible Initial Pulmonary Tuberculosis Patients in China
    MA Yan
    HUANG Mai Ling
    LI Tao
    DU Jian
    SHU Wei
    XIE Shi Heng
    WANG Hong Hong
    ZHU Guo Feng
    TAN Shou Yong
    FU Yan Yong
    MA Li Ping
    ZHANG Lian Ying
    LIU Fei Ying
    HU Dai Yu
    ZHANG Yan Ling
    LI Xiang Qun
    LIU Yu Hong
    LI Liang
    Biomedical and Environmental Sciences, 2017, 30 (09) : 671 - 675
  • [3] Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
    Andrew J Nunn
    ID Rusen
    Armand Van Deun
    Gabriela Torrea
    Patrick PJ Phillips
    Chen-Yuan Chiang
    S Bertel Squire
    Jason Madan
    Sarah K Meredith
    Trials, 15
  • [4] Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
    Nunn, Andrew J.
    Rusen, I. D.
    Van Deun, Armand
    Torrea, Gabriela
    Phillips, Patrick P. J.
    Chiang, Chen-Yuan
    Squire, S. Bertel
    Madan, Jason
    Meredith, Sarah K.
    TRIALS, 2014, 15
  • [5] Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial
    Mengqiu Gao
    Jingtao Gao
    Jian Du
    Yuhong Liu
    Yao Zhang
    Liping Ma
    Fengling Mi
    Liang Li
    Shenjie Tang
    BMC Infectious Diseases, 17
  • [6] Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial
    Gao, Mengqiu
    Gao, Jingtao
    Du, Jian
    Liu, Yuhong
    Zhang, Yao
    Ma, Liping
    Mi, Fengling
    Li, Liang
    Tang, Shenjie
    BMC INFECTIOUS DISEASES, 2017, 17
  • [7] Role Of Tobacco Cessation As An Adjunct To Anti-Tuberculosis Treatment In Pulmonary Tuberculosis: An Open-Label, Randomized, Controlled Clinical Trial
    Sharma, S. K.
    Mohan, A.
    Mishra, H.
    Singh, A. D.
    Jhanhi, S.
    Pandey, R.
    Pallipamu, P.
    Singh, B.
    Yadav, R.
    Dheda, K.
    Theron, G.
    Sengupta, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial
    Zhen Feng
    Yan Miao
    Ying Peng
    Feng Sun
    Yilin Zhang
    Rong Li
    Shijia Ge
    Xinchang Chen
    Lingyun Song
    Yang Li
    Xiaomeng Wang
    Wenhong Zhang
    BMC Infectious Diseases, 23
  • [9] Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial
    Feng, Zhen
    Miao, Yan
    Peng, Ying
    Sun, Feng
    Zhang, Yilin
    Li, Rong
    Ge, Shijia
    Chen, Xinchang
    Song, Lingyun
    Li, Yang
    Wang, Xiaomeng
    Zhang, Wenhong
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [10] The effectiveness of silymarin in the prevention of anti-tuberculosis drug-induced hepatotoxicity: A randomized controlled clinical trial
    Talebi, Ali
    Soltani, Rasool
    Khorvash, Farzin
    Jouabadi, Soroush Mohammadi
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2023, 14 (01)
12345